Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis

Osteoporosis International

Volumn 12, Issue 11, 2001, Pages 922-930

  Bjarnason, N H ^a   Sarkar, S ^b   Duong, T ^c   Mitlak, B ^b   Delmas, P D ^d   Christiansen, C ^a  

^a CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

BMD; Bone turnover; Osteoporosis; Raloxifene; Vertebral fracture

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; OSTEOCALCIN; RALOXIFENE;

ADULT; AGED; ARTICLE; BONE TURNOVER; CONTROLLED STUDY; DENSITOMETRY; DISEASE MARKER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SPINE RADIOGRAPHY; STATISTICAL ANALYSIS; VERTEBRA FRACTURE;

ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE REMODELING; CHI-SQUARE DISTRIBUTION; COLLAGEN; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE; RISK FACTORS; SPINAL FRACTURES;

EID: 0035664686     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001980170020     Document Type: Article

References (40)

1. Consensus development statement. 1997 Who are candidates for prevention and treatment for osteoporosis?
2. Low doses of estradiol in combination with gestodene to prevent early postmenopausal bone loss
3. Alendronate and estrogen-progestin in the longterm prevention of bone loss: Four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial
4. The effect on bone mass and bone markers of different doses of ibandronate, a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1-year, randomized, double-blind, placebo-controlled dose-finding study
5. Risedronate increases bone mass in an early postmenopausal population: Two years of treatment plus one year of follow-up
6. Tibolone: Prevention of bone loss in late postmenopausal women
7. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
8. Treatment of postmenopausal osteoporosis with transdermal estrogen
9. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
10. Effects of risedronate treatment in vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomised controlled trial
11. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
12. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose-response study
13. Noninvasive assessment of bone mineral and structure: State of the art
14. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment
15. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: A randomized clinical trial
16. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women
17. A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover
18. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort (EPIC) study
19. Serum CTX: A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy
20. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: Prediction of bone mass changes during treatment
21. Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers
22. Biochemical markers of bone turnover to monitor the bone response to postmenopausal hormone replacement therapy
23. Hormone replacement therapy in postmenopausal women: Urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density
24. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation
25. Early response in biochemical markers predicts long-term response in bone mass during HRT in early postmenopausal women
26. Monitoring individual response to hormone replacement therapy with bone markers
27. The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women
28. Applications of an enzyme immunoassay for a new markers of bone resorption (CrossLaps): Follow-up on hormone replacement therapy and osteoporosis risk assessment
29. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease
30. Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay
31. Prevalent vertebral deformities predict hip fractures and new vertebral deformities, but not wrist fractures
32. Pre-existing fracture and bone mass predict vertebral fracture incidence in women
33. How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis?
34. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS Prospective Study
35. Serum CrossLaps One Step ELISA for monitoring the response in individuals undergoing anti-resorptive therapy
36. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fracture in women with postmenopausal osteoporosis
37. Effects of raloxifene (rlx), alendronate (aln) and rlx+aln on bone mineral density (BMD) and biochemical markers of bone turnover in postmenopausal women
38. Antifracture efficacy of antiresorptive agents is related to changes in bone density
39. Changes in BMD substantially underestimate the anti-fracture effect of alendronate and other antiresorptive drugs
40. What proportion of the effects of raloxifene (rlx) on vertebral fracture risk and be directly attributed to its bone mineral density (BMD) effects?